TCGX
TCGX closes $600M fund to invest in Asian biotech
TCGX has closed an oversubscribed $600 million fund to invest across stages in Asia-based biotechnology companies and is opening Hong Kong and Shanghai offices.
TCGX has closed an oversubscribed $600 million fund to invest across stages in Asia-based biotechnology companies and is opening Hong Kong and Shanghai offices.
